Defective Extracellular Pyrophosphate Metabolism Promotes Vascular Calcification in a Mouse Model of Hutchinson-Gilford Progeria Syndrome that is Ameliorated upon Pyrophosphate Treatment

Running title: Villa-Bellosta et al.; Defective extracellular pyrophosphate in HGPS

Ricardo Villa-Bellosta, PhD\(^1\); José Rivera, PhD\(^1\); Fernando G. Osorio, Msc\(^2\); Rebeca Acín-Pérez, PhD\(^3\); José A. Enriquez, PhD\(^3\); Carlos López-Otín, PhD\(^2\); Vicente Andrés, PhD\(^1\)

\(^1\)Dept of Epidemiology, Atherothrombosis and Imaging, Centro Nacional de Investigaciones Cardiovasculares, Madrid; \(^2\)Dept de Bioquímica y Biología Molecular, Universidad de Oviedo-IUOPA, Oviedo; \(^3\)Dept of Cardiovascular Development and Repair, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain

Address for Correspondence:
Vicente Andrés, PhD
Centro Nacional de Investigaciones Cardiovasculares
Melchor Fernández Almagro 3
28029 Madrid, Spain
Tel: +34914531200, extension 1502
Fax: +34914531245
E-mail: vandres@cnic.es

Journal Subject Codes: Basic science research:[130] Animal models of human disease, Vascular biology:[97] Other vascular biology
Abstract:

Background—Progerin is a mutant form of lamin A responsible for Hutchinson-Gilford progeria syndrome (HGPS), a premature aging disorder characterized by excessive atherosclerosis and vascular calcification that leads to premature death, predominantly from myocardial infarction or stroke. The goal of this study was to investigate mechanisms causing excessive vascular calcification in HGPS.

Methods and Results—We performed expression and functional studies in wild-type mice and knock-in \( Lmna^{G609G/+} \) mice expressing progerin, which mimic the main clinical manifestations of HGPS. \( Lmna^{G609G/+} \) mice showed excessive aortic calcification, and primary aortic vascular smooth muscle cells (VSMCs) from these progeroid animals have an impaired capacity to inhibit vascular calcification. This defect in progerin-expressing VSMCs is associated with increased tissue expression and activity of tissue-nonspecific alkaline phosphatase (TNAP) and mitochondrial dysfunction leading to reduced ATP synthesis. Accordingly, \( Lmna^{G609G/+} \) VSMCs are defective for the production and extracellular accumulation of pyrophosphate, a major inhibitor of vascular calcification. We also found increased alkaline phosphatase activity and reduced ATP and pyrophosphate levels in plasma of \( Lmna^{G609G/+} \) mice without changes in phosphorus and calcium. Treatment with pyrophosphate inhibited vascular calcification in progeroid mice.

Conclusions—Excessive vascular calcification in \( Lmna^{G609G} \) mice is caused by reduced extracellular accumulation of pyrophosphate resulting from increased TNAP activity and diminished ATP availability caused by mitochondrial dysfunction in VSMCs. Excessive calcification is ameliorated upon pyrophosphate treatment. These findings reveal a previously undefined pathogenic process in HGPS that may also contribute to vascular calcification in normal aging, since progerin progressively accumulates in the vascular tissue of non-HGPS individuals.

Key words: aging, basic science, lamin A/C, smooth muscle cell, vascular calcification, progerin, Hutchinson-Gilford progeria syndrome, pyrophosphate
Introduction

Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare sporadic genetic disorder that is characterized by accelerated cardiovascular disease and premature aging.\textsuperscript{1,2} Most (>90%) HGPS patients carry a non-inherited autosomal dominant de novo heterozygous mutation at codon 608 of the \textit{LMNA} gene (c.1824C>T: GGC>GGT; p.G608G). This mutation activates a cryptic splice donor site, causing the synthesis of progerin.\textsuperscript{1,2} Expression of this lamin A mutant disrupts the nuclear membrane architecture and causes multiple cellular alterations, including impaired DNA repair capacity and abnormal higher-order chromatin organization, gene transcription and signal transduction.\textsuperscript{3,4} HGPS patients exhibit accelerated atherosclerosis and die at a mean age of 13.4 years (range, 8-21 years) predominantly from myocardial infarction or stroke.\textsuperscript{5-7} Additional clinical HGPS manifestations include dermal and bone abnormalities, alopecia and joint contractures.\textsuperscript{5,8-16} Moreover, the aortas and aortic valves of HGPS patients are excessively calcified,\textsuperscript{10-12} and arteries from old transgenic mice carrying a human bacterial artificial chromosome that harbors the common HGPS mutation accumulate calcium deposits that are absent in age-matched controls.\textsuperscript{17} However, the mechanisms underlying excessive vascular calcification in HGPS remain unexplored.

Vascular calcification typically manifests as calcium-phosphate deposition (CPD) in distinct layers of the aortic wall.\textsuperscript{18,19} Calcium-phosphate deposits are composed of several members of the calcium orthophosphate family, including hydroxyapatite, octocalcium phosphate and amorphous calcium phosphate.\textsuperscript{20} Medial calcification occurs within the elastin region of arteries and is almost exclusively associated with vascular smooth muscle cells (VSMCs). Elevated serum phosphorus (in the form of inorganic phosphate) is a major risk factor for vascular calcification.\textsuperscript{21,22} \textit{In vitro} and \textit{in vivo} studies have shown that elevated inorganic
phosphate concentration in VSMCs triggers a transition to a bone-forming phenotype.\textsuperscript{18, 19} This transition results in over-expression of osteochondrogenic markers, such as the transcription factor Runx2 (also named Cbfa1), which induces the expression of major bone matrix components.\textsuperscript{18, 19}

Extracellular pyrophosphate (ePPi) directly blocks CPD \textit{in vitro} and \textit{in vivo} and is therefore a major endogenous inhibitor of vascular calcification.\textsuperscript{23-26} Degradation of ePPi is catalyzed by tissue-nonspecific alkaline phosphatase (TNAP), which hydrolyzes PPI to inorganic phosphate. Importantly, calcification in \textit{ex vivo} cultured rat aorta is induced by alkaline phosphatase and is prevented by TNAP inhibitors.\textsuperscript{26, 27} TNAP is moreover up-regulated in the aortas of uremic rats, resulting in increased hydrolysis of ePPi and vascular calcification.\textsuperscript{28} The main enzyme involved in ePPi synthesis, both in aorta and in cultured VSMCs, is the \textit{ectoenzyme nucleotide pyrophosphatase/phosphodiesterase-1} (eNPP1).\textsuperscript{26, 29} Lack of eNPP1 leads to extensive and fatal arterial calcification in children and mice.\textsuperscript{30, 31} The substrate for eNPP1 is ATP, which accumulates in the extracellular matrix via the action of several transporters,\textsuperscript{32} such as the multiple-pass transmembrane protein ANK.\textsuperscript{33}

To define the molecular mechanisms that lead to vascular calcification in HGPS, we analyzed \textit{Lmna}\textsuperscript{G609G} knock-in mice, which express progerin as a consequence of aberrant splicing resulting from the \textit{LMNA} c.1827C>T (p.G609G) mutation, equivalent to the human mutation c.1824C>T (p.G608G).\textsuperscript{34} This new mouse model of progeria mimics the main clinical manifestations of human HGPS, including cardiovascular aberrations and premature death.\textsuperscript{34} Our studies reveal profound alterations in ePPi homeostasis caused by progerin expression that exacerbate vascular calcification, which is inhibited by pyrophosphate treatment.
Methods

Mice

Male \( Lmna^{G609G/+} \), \( Lmna^{G609G/G609G} \) and wild-type littermates were used.\(^{34}\) Animal studies were approved by the local ethics committee and conformed to Directive 2010/63/EU and Recommendation 2007/526/EC regarding the protection of animals used for experimental and other scientific purposes, enforced in Spanish law under Real Decreto 1201/2005.

Cell culture

VSMCs were prepared from thoracic aortas of 30-32-week-old mice as described previously.\(^{35}\) Cells were grown in minimal essential medium (MEM) containing 1 mM L-glutamine, 100 IU/ml penicillin, 100 \( \mu \)g/ml streptomycin and 10% fetal bovine serum (FBS) at 37°C in a humidified atmosphere at 5% CO\(_2\). VSMCs were used at passages 5-10. Cells were grown to confluence and used after an overnight quiescence step (0.1% FBS). Calcification assays were performed on cells incubated for 7 days in MEM supplemented with 0.1% FBS and 2 mmol/L Pi as described previously.\(^{35,36}\) For phosphatase activity studies and ATP and PPi measurements, VSMCs were incubated in medium without Phenol Red.

Quantification of calcium deposition

Aortic arch and thoracic aorta from wild-type and \( Lmna^{G609G/+} \) mice (\( n = 5 \) per genotype) were included in OCT (Sakura, Netherlands), and 4-\( \mu \)m cross-sections were cut with a cryostat (Leica CM1950, Barcelona, Spain). Calcification in aortic tissue was revealed by Alizarin red staining as described.\(^{35,36}\) To quantify calcium deposits, 2-4 aortic cross-sections of each mouse were analyzed with ImageJ (http://imagej.nih.gov/ij/docs/guide).

To quantify calcium content in VSMCs, cells were treated with 0.6 HCl overnight at 4°C and analyzed with a colorimetric QuantiChrom calcium assay kit (BioAssay Systems, Hayward,
California).

**Pyrophosphate treatment in vivo**

PPi (Sigma, S6422) was dissolved in sterile saline (B.Braun Medical SA, Barcelona, Spain). 10-week-old Lmna<sup>G609G/G609G</sup> mice were treated with PPi for 9 weeks (daily intraperitoneal injection, 100 mg/Kg/day) and the control group received saline (n=5 mice in each group). Quantification of aortic calcification was performed as indicated above.

**Quantitative real-time PCR (qPCR)**

Total RNA was isolated from mouse aorta or VSMCs using Qiazol lysis reagent (Qiagen, Madrid, Spain). After DNase treatment, 2 µg RNA was reverse transcribed using the High capacity cDNA reverse transcription kit (Applied Biosystems, Madrid, Spain). qPCR was performed using Power SYBR Green in 384-well clear optical reaction plates on an ABI PRISM 7900HT Sequence Detection System following the manufacturer’s instructions for calibrator normalization (Applied Biosystems). All reactions were carried out in triplicate. The primers used for amplification were as follows: 1) **BMP-2** (NM_007553): 5’-CACCCTGCGCAGCTTCCA-3’ (forward), 5’-CCGGGCCGTTTTCCCACTCA-3’ (reverse); 2) **Runx2** (NM_001146038.1): 5’-CAGATCCCAGGCAGGCACAGTC-3’ (forward), 5’-ACACCGGCGTGTGGAGTG-3’ (reverse); 3) **eNPP1** (NM_008813): 5’-GAGATCCCCAGGCAGGCACAGTC-3’ (forward), 5’-ACACCGGCGTGTGGAGTG-3’ (reverse); 4) **TNAP** (NM_007431): 5’-CTATGTCTGGAACCGCACTGA-3’ (forward), 5’-AGCCTTTGAGGTTTTTGGTCA-3’ (reverse); 5) **Pit1** (NM_015747): 5’-CTGCTTCACGAGTGGTAGAG-3’ (forward), 5’-TGTAACCTACGGCAGCAGGAAAC-3’ (reverse); 6) **Pit2** (NM_011394): 5’-CTCTACAACGAGACCGGGAGAAGTGG-3’ (forward), 5’-CATGAAGCCAGAAAGAAGTGG-3’ (reverse); 7) **ANK** (NM_020332): 5’-
CATCCCCATCTGTCTCTGTA-3' (forward), 5'- ACACGAAGAGTTGACAATGG -3' (reverse); 8) **Entpd1** (NM_009848): 5'-AGCCTCCACACAGATCACCTT-3' (forward), 5'- GCCACCCTTGAACCTGAAT -3' (reverse); 9) **Fetuin A** (NM_013465): 5'-
ATCGACAAAGTCAAGGTG-3' (forward), 5'- CAACCTACGAACGTCTCTGC -3' (reverse); 10) **Matrix Gla-protein** (NM_008597): 5'-AGGAGAAATGCCAACCTTT-3' (forward), 5'- ACGAAAACCTCACAACCAAATG -3' (reverse). Expression was quantified by the comparative C_T method, with correction for the expression of the endogenous control gene acidic ribosomal phosphoprotein P0 (RPLP0, accession number NM_00775).

**Immunoblots and immunohistochemistry**

VSMC lysates were prepared in lysis buffer (0.1% SDS, 25 mM Tris-HCl pH 7.4 and protease inhibitors) and 30-50 μg protein were separated by SDS-PAGE and blotted to PVDF membrane as previously described. The following primary antibodies were used: rabbit monoclonal anti-eNTPD1 (1/5000, ab108248, Abcam, Cambridge, UK), rabbit polyclonal anti-TNAP (1 μg/ml, ab65834, Abcam), rabbit polyclonal anti-GFP (1/2500, ab6556, Abcam) and mouse monoclonal anti-α-Tubulin (1/5000, sc-8035, Santa Cruz biotechnology, USA). After incubation with appropriate secondary antibodies, blots were revealed using the ECL system (Millipore, Billerica, MA, USA). Mouse aortas were immunohistochemically stained with a rabbit polyclonal antibody to Runx2 (1/500, ab102711, Abcam).

**Phosphatase activity and ATP hydrolysis assays**

Phosphatase activity in VSMCs or plasma was measured using the pNPP phosphatase assay kit and the Quantichrom alkaline phosphatase assay kit (BioAssay Systems), respectively. ATP hydrolysis assays in VSMCs cultures were performed as previously described. Briefly, cells were seeded in 12-well plates and incubated for the indicated times with 1 μM ATP and 1...
μCi/mL [γ³²P]ATP radiotracer (Perkin Elmer, Madrid, Spain). ATP, inorganic phosphate and PPi in the culture medium were then separated by chromatography on PEI-cellulose plates and were developed with 650 mM KH₂PO₄ pH 3. After autoradiography, spots were excised and counted by liquid scintillation.

**ATP and pyrophosphate quantification**

ePPi was measured using an enzyme-linked bioluminescence assay in which PPi reacts with adenosine 5’-phosphosulfate (A5508, Sigma) in the presence of ATP-sulfurylase (A8957, Sigma) to generate ATP. For each sample, the blank (reaction without ATP-sulfurylase) was subtracted to obtain the true PPi amount. ATP was measured by a coupled luciferin/luciferase reaction using an ATP determination kit (Invitrogen, Paisley, UK).

**Generation of retroviral vectors and stable cell lines**

Wild-type pre-lamin A and progerin cDNAs were PCR amplified using as template a previously published construct or Addgene plasmid #17663, respectively. Amplicons were inserted into pECPF vector (Clontech). CFP-pre-lamin A and progerin-CFP were then subcloned into pMSCVpuro retroviral vector (Clontech, Moustain View, CA) after digestion with XhoI/EcoRI to respectively generate pMSCVpuro/CFP-pre-lamin A (which is post-translationaly modified to generate mature lamin A) and pMSCVpuro/Progerin-CFP. Correct cloning of both plasmids was verified by DNA sequencing. The precise primer sequences and cloning strategies are available upon request. To generate retroviral stocks, 5×10⁶ HEK-293T cells were plated in 100 mm dishes. After 12 h, cells were transfected (Lipofectamine 2000; Invitrogen) with 10 μg pCL-Ecotropic vector and 10 μg of the desired plasmid (pMSCVpuro/CFP-pre-lamin A or pMSCVpuro/Progerin-CFP). Two days post-transfection, supernatants were harvested and filtered to obtain retroviral stocks. Primary VSMCs prepared from the aortas of 8-week-old
C57BL/6J mice were incubated for 4 hr at 37°C with retroviral supernatant supplemented with 4 μg/mL polybrene. After 3 rounds of infection, cells were washed once with PBS and cultured in growth medium in the presence of 1 μg/mL puromycin until complete selection was achieved (passages 6-7). The subpopulations of cells expressing the CFP recombinant proteins were obtained using a fluorescence-activated cell sorter (FACS Aria III cell sorter, BD Bioscience, San José, CA, EE.UU.).

**Mitochondrial assays**

Mitochondrial ATP synthesis in digitonin-permeabilized VSMCs (2x10^6 cells) was measured by kinetic luminescence assay. Cytochrome c oxidase (COX) and citrate synthase (CS) enzymatic activities were measured in cell lysates (30–50 μg protein) as described, and expressed as international units (IU) per mg protein. COX activity was normalized to CS, a Krebs cycle enzyme used as an index of mitochondrial mass.

**Statistical analysis**

Results are expressed as mean±SEM. For the studies shown in Figure 1, 2, 3, 4 and 5A, results were analyzed using unpaired Student’s t-test with Welch’s correction for two samples with possibly unequal variance. The results in Figure 5B were analyzed using paired Student’s t-test. In all cases, statistical significance was assigned at p<0.05.

**Results**

**Vascular smooth muscle calcification is increased in progeroid Lmna<sup>G609G/+</sup> mice**

HGPS patients carry the LMNA mutation in heterozygosis and express both lamin A and progerin. We therefore performed studies with heterozygous Lmna<sup>G609G/+</sup> mice that also express lamin A and progerin and have a significantly shortened lifespan (average 34 weeks,
compared with more than 2 years for wild-type controls)\textsuperscript{34}. We used 30-32-week-old 
\textit{Lmna}\textsuperscript{G609G/+} mice. Gross examination of Alizarin Red-stained vessels revealed prominent medial 
calcification in aortic arch and thoracic aorta of \textit{Lmna}\textsuperscript{G609G/+} compared with wild-type mice, and 
computer-assisted planimetric analysis showed statistically significant differences between 
genotypes (Fig. 1A). Consistent with these findings, qPCR revealed that calcified aortas from 
\textit{Lmna}\textsuperscript{G609G/+} mice have high mRNA levels of BMP-2 and Runx2, two osteogenic markers 
expressed during vascular calcification, but no changes were observed in the anti-calcification 
agents matrix Gla-protein (MGP) and fetuin A (Fig. 1B, C). Immunohistochemical analysis 
confirmed the increase in Runx2 expression in \textit{Lmna}\textsuperscript{G609G/+} aortas compared with aortas from 
wild-type mice (Fig. 1D).

We next studied primary cultures of VSMCs isolated from aortic tissue of wild-type and 
\textit{Lmna}\textsuperscript{G609G/+} mice. Previous \textit{in vitro} studies showed that CPD is more prominent with lysed 
VSMCs than with live cells, suggesting that VSMCs synthesize CPD inhibitors.\textsuperscript{25, 35, 36} We 
therefore compared the CPD-inhibitory capacity of wild-type and \textit{Lmna}\textsuperscript{G609G/+} VSMCs. Cells 
were incubated for 7 days in calcifying medium, and the difference in CPD between lysed and 
live cells (\(\Delta \text{Ca}^{2+}\)) was calculated. \textit{Lmna}\textsuperscript{G609G/+} VSMCs showed a significantly lower capacity to 
inhibit calcium deposition than equivalent numbers of control cells, after normalization for 
protein concentration (Fig. 1E).

\textit{Lmna}\textsuperscript{G609G/+} VSMCs have an impaired capacity to synthesize extracellular pyrophosphate

Since excessive calcification in \textit{Lmna}\textsuperscript{G609G/+} aorta was not associated with reduced expression of 
MGP and fetuin A (Fig. 1B), we quantified in VSMC-conditioned culture medium the 
accumulation of ePPI, the major endogenous inhibitor of vascular calcification.\textsuperscript{21, 23-26} After 2 
days in culture, ePPI levels were 3.8-fold lower in \textit{Lmna}\textsuperscript{G609G/+} VSMCs compared with wild-type
controls (Fig.2A). RT-PCR analysis of enzymes and transporters involved in ePPi metabolism demonstrated significantly higher expression of TNAP, Apyrase1 (Entpd1) and the phosphate transporter Pit2 in Lmna<sup>G609G/+</sup> compared with wild-type VSMCs, whereas eNPP1, ANK and Pit1 were unaffected (Fig.2B). Western blot analysis confirmed the increase in the ectoenzymes TNAP and eNTPD1 in Lmna<sup>G609G/+</sup> VSMCs (Fig.2C). Moreover, phosphatase activity was 2-fold higher in Lmna<sup>G609G/+</sup> VSMCs (Fig.2D).

Given these findings, we next investigated the capacity of Lmna<sup>G609G/+</sup> VSMCs to synthesize PPi using ATP as substrate. Cells were incubated for different times with 1 μM ATP and [γ<sup>32</sup>P]-ATP radiotracer, and radioactive ATP, PPi and inorganic phosphate (Pi) were quantified in the culture medium after separation by thin-layer chromatography (Fig.2E). Wild-type and Lmna<sup>G609G/+</sup> VSMCs showed indistinguishable rates of ATP hydrolysis, with approximately 98% of ATP being hydrolyzed after 80 minutes (Fig.2E). However, the amount of ePPi produced was only 28% in Lmna<sup>G609G/+</sup> VSMCs, compared with 47% in wild-type cells, and the amount of Pi produced was 68% in Lmna<sup>G609G/+</sup> VSMCs compared with 49% in wild-type cells (Fig.2E). Accordingly, the Pi:PPi ratio increased from ~1:1 in wild-type VSMCs to ~2.4:1 in Lmna<sup>G609G/+</sup> VSMCs.

**VSMCs expressing progerin have impaired ATP synthesis and mitochondrial function**

Extracellular ATP hydrolysis is the major source of ePPi in aorta and in VSMCs. We therefore analyzed intracellular ATP levels and extracellular ATP accumulation in wild-type and Lmna<sup>G609G/+</sup> VSMCs. Lmna<sup>G609G/+</sup> VSMCs showed significantly lower levels of extracellular ATP (Fig.3A) and intracellular ATP (Fig.3B). Lmna<sup>G609G/+</sup> VSMCs also exhibited lower mitochondrial ATP production (Fig.3C). This was associated with a significantly lower COX/CS ratio (Fig.3D), indicating impaired activity of COX, an essential component of complex IV in
the mitochondrial electron transport chain.

To assess whether the alterations observed in \( Lmna^{G609G/+} \) VSMCs are a direct consequence of progerin expression, we performed retrovirus-mediated gain-of-function experiments. Western blot analysis demonstrated CFP-lamin A and progerin-CFP expression in primary mouse VSMCs infected with retrovirus encoding these proteins (\( \text{Fig.4A} \)). In agreement with many previous studies in different cell types, infected VSMCs expressed CFP-lamin A predominantly in the perinuclear rim, whereas progerin-CFP was found in both the perinuclear rim and in nucleoplasmic aggregates (\( \text{Fig.4B} \)). Compared with VSMCs expressing CFP-lamin A, forced progerin expression in VSMCs led to increased TNAP and Apyrase1/eNTPD1 mRNA steady-state levels without affecting the expression of others enzymes and transporters involved in ePPi metabolism (\( \text{Fig.4C} \)). Western blot analysis confirmed the increase in TNAP and eNTPD1 in \( Lmna^{G609G/+} \) VSMCs overexpressing progerin (\( \text{Fig.4D} \)). Consistent with the results in primary \( Lmna^{G609G/+} \) VSMCs, we also found significant reductions in extracellular and intracellular ATP concentration, mitochondrial ATP synthesis, COX/CS ratio, and ePPi levels in progerin-CFP-overexpressing VSMCs compared with CFP-lamin A-expressing controls (\( \text{Fig.4E} \)).

**Progerin expression in \( Lmna^{G609G/-} \) mice affects plasma parameters involved in vascular calcification**

Since hyperphosphatemia and hypercalcemia lead to CPD,\(^{19}\) we quantified inorganic phosphate and calcium in plasma from wild-type and \( Lmna^{G609G/+} \) mice (\( \text{Fig.5A} \)). These parameters were similar in both genotypes (phosphorus: 8.2±0.2 in wild-type versus 7.7±0.3 mg/dl in \( Lmna^{G609G/+} \); calcium: 14.4±0.3 in wild-type versus 14.8±0.3 mg/dl in \( Lmna^{G609G/+} \); \( p>0.05 \)). However, the plasma of \( Lmna^{G609G/+} \) mice exhibited higher alkaline phosphatase activity (29.5%
higher) and lower concentrations of ATP (8-fold) and ePPi (9-fold) (Fig.5A).

**Pyrophosphate treatment inhibits aortic calcification in progeroid mice.** Recent studies showed that injection of exogenous PPi prevents uremic vascular calcification in rats and mice.\(^{24,39}\) We therefore investigated the effect of PPi injection on vascular calcification in progeroid mice. For these studies, we used homozygous \(Lmna^{G609G/G609G}\) mice, which are more severely affected than heterozygous \(Lmna^{G609G/+}\) mice, with an average lifespan of only 103 days.\(^{34}\) Ten-week-old homozygous \(Lmna^{G609G/G609G}\) males received daily intraperitoneal injections of saline (control group) or PPi over 9 weeks (100 mg/kg/day, \(n=5\) mice in each group). We did not observe differences in body weight and mortality during follow-up, but post-mortem analysis demonstrated a statistically-significant reduction in aortic calcification in PPi-treated mice compared with controls, as revealed by planimetric analysis of Alizarin Red-stained aortic cross-sections (Fig.5B).

**Discussion**

The aim of the present study was to identify molecular mechanisms that contribute to excessive vascular calcification in HGPS, a rare premature aging disorder caused by abnormal expression of progerin.\(^1,2\) Available evidence indicates that vascular calcification involves both passive and active processes\(^{18,19,25}\) (Fig.6). CPD in the aortic wall and in *in vitro* models is the main feature of vascular calcification. At physiological serum concentrations of calcium and phosphate, CPD is a passive process that does not require cellular activity.\(^{20,25,36,40}\) Active processes involved in vascular calcification include reduced capacity of VSMCs to synthesize and secrete calcification inhibitors, such as MGP, fetuin A and ePPi, and the transition of VSMCs to a bone-forming phenotype, a process that is enhanced via CDP-dependent overexpression of osteochondrogenic
factors, including Runx2.\textsuperscript{18, 19, 36, 41} Inorganic phosphate is essential for the synthesis of ATP, the main source of ePPi.\textsuperscript{26} It has thus been proposed that defective ATP production by VSMCs may impair the synthesis of CPD inhibitors.\textsuperscript{42} Previous studies revealed that old transgenic mice carrying the common HGPS mutation exhibit a vascular calcification not seen in age-matched controls.\textsuperscript{17} However, the mechanisms by which progerin exacerbates vascular calcification remain unknown. Here, we have shown that progerin expression in \emph{Lmna}^G609G/+ mice causes excessive vascular calcification associated with VSMC abnormalities that lead to impaired mitochondrial function and ATP production and reduced PPi synthesis (Fig.6), without affecting expression of the anti-calcification agents MGP and fetuin A. The causal relationship between progerin-induced low plasma ePPi and vascular calcification is reinforced by our observation that aortic calcification in progeroid mice is reduced by treatment with PPi. It is noteworthy that physiological aging of non-HGPS individuals is associated with mitochondrial dysfunction\textsuperscript{43, 44} and with a progressive accumulation of progerin in several tissues,\textsuperscript{45-48} including vascular tissue.\textsuperscript{6} Thus our findings might be relevant to vascular calcification not only in HGPS patients but also in the elderly.

Since HGPS patients carry the \emph{LMNA} mutation in heterozygosis,\textsuperscript{1, 2} we studied heterozygous \emph{Lmna}^{G609G/+} mice that express both lamin A and progerin.\textsuperscript{34} We found excessive aortic calcification in progeroid \emph{Lmna}^{G609G/+} mice, which was associated with increased expression of Runx2 and Bmp-2, two osteochondrogenic markers expressed in VSMCs during calcification \textit{in vivo} and \textit{in vitro}\textsuperscript{19} that are induced by CPD.\textsuperscript{36, 41} Importantly, VSMCs from \emph{Lmna}^{G609G/+} mice also exhibited an impaired capacity to inhibit CPD \textit{in vitro}, which might explain the excessive medial calcification and the consequent overexpression of osteogenic markers in the aorta of \emph{Lmna}^{G609G/+} mice. To investigate the molecular mechanisms through
which progerin triggers vascular calcification, we focused on the enzymes and transporters involved in ePPi homeostasis, a complex process that involves a balance between synthesis and degradation. Our results provide evidence that excessive vascular calcification in \( Lmna^{G609G/+} \) mice is the consequence of alterations in VSMCs, including impaired synthesis of PPi, which leads to reduced accumulation of ePPi (Fig.6). Additional factors contributing to progerin-dependent reduction in ePPi levels include the upregulation of the ectoenzymes TNAP (the main enzyme involved in ePPi hydrolysis) and apyrase1/eNTPD (an enzyme that hydrolyzes ATP to release Pi), and low synthesis of ATP (the major substrate for ePPi synthesis). Our studies suggest that impaired ATP synthesis in \( Lmna^{G609G/+} \) VSMCs is due to mitochondrial dysfunction associated with reduced complex IV COX activity. Importantly, retrovirus-mediated overexpression of progerin recapitulates the alterations observed in primary VSMCs isolated from \( Lmna^{G609G/+} \) mice, including increased expression of TNAP and apyrase1/eNTPD, reduced extracellular and intracellular ATP, diminished mitochondrial COX-CS ratio and ATP synthesis, and lower ePPi accumulation. A-type lamins have been linked to the regulation of multiple cellular processes (e.g., higher-order chromatin organization, DNA repair and replication, signal transduction, gene transcription, and cell proliferation, differentiation and migration), many of which are altered upon progerin expression.\(^3,4\) Therefore additional studies are required to refine our understanding of the molecular mechanisms through which progerin expression alters VSMC behavior to promote calcification.

Hyperphosphatemia causes vascular calcification, thus underscoring the importance of inorganic phosphate homeostasis in CPD. However, in a study of 15 HGPS patients with a wide age range of 1.6-17.8 years, Merideth et al.\(^5\) reported a plasma phosphorus concentration of 5.5±0.2 mg/dl, which is within the normal range in humans (2.7-5.5 mg/dl). We also found that
Lmna<sup>G609G/+</sup> mice have plasma phosphate concentrations in the normal range, undistinguishable from their wild-type littermates (~8 mg/dl; normal range in mice: 5.7-9.2 mg/dl). Likewise, plasma calcium levels were normal in progeroid mice. These results indicate that hyperphosphatemia and hypercalcemia do not contribute to excessive vascular calcification in Lmna<sup>G609G/+</sup> mice, thus emphasizing the importance of reduced synthesis of ePPi by VSMCs as a key mechanism triggering excessive vascular calcification in HGPS. Although plasma phosphate levels are normal in Lmna<sup>G609G/+</sup> mice, increased accumulation of Pi in the tunica media may contribute to CPD in these animals, since our results in primary VSMCs from Lmna<sup>G609G/+</sup> mice show augmented Pi production from ATP hydrolysis accompanied by a high Pi:PPi ratio of ~2.4:1, compared with ~1:1 in wild-type cells (Fig. 2E). The defect in ePPi production by progerin-expressing VSMCs is unlikely to be counterbalanced systemically, since PPi concentration in plasma from Lmna<sup>G609G/+</sup> mice was also significantly reduced compared with wild-type controls, probably as a result of lower ATP concentration and higher alkaline phosphatase activity in plasma. Our observation that PPi treatment inhibits aortic calcification in progeroid mice underscores the role of defective ePPi homeostasis as a key factor underlying excessive vascular calcification in HGPS. We did not observe changes in body weight or mortality upon PPi treatment. However, it is important to note that these studies were performed in homozygous Lmna<sup>G609G/G609G</sup> mice that have an average life span of only 15 weeks<sup>34</sup> and treatment was started at 10 weeks of age, when the animals already exhibit severe symptoms<sup>34</sup>. HGPS patients carry the LMNA mutation in heterozygosis<sup>1,2</sup> and therefore future studies are warranted in very young heterozygous Lmna<sup>G609G/+</sup> mice (1-2-weeks-old) to ascertain whether chronic treatment with PPi starting early in life, when symptoms are absent or very mild, can not only inhibit vascular calcification but also improve the general health and lifespan of progeroid
mice.

Since imbalances in the degradation and synthesis of ePPi have been shown to lead to pathologic calcification of articular cartilage, the systemic defect in circulating PPI associated with progerin expression might promote not only excessive vascular calcification but also the appearance of joint contractures, a characteristic of both HGPS patients and Lmna \( G^{609G} \) mice. Treatment with PPI might thus ameliorate both vascular calcification and joint contractures. It is noteworthy that combined treatment with statins and bisphosphonates (nonhydrolyzable pyrophosphate analogues) significantly extends the average lifespan of progeroid Zmpste24/- mice, another model of premature aging caused by abnormal accumulation of prelamin A. Based on these findings, ongoing clinical trials are assessing the efficacy of statin plus bisphosphonate (pravastatin plus zolendrate) with or without farnesyl transferase inhibitor (http://www.progeriaresearch.org/clinical_trial.html). However, although treatment with bisphosphonates decreases aortic calcification, animal studies have identified adverse effects of these compounds in bone. Moreover, bisphosphonates have been shown to induce the rupture of atherosclerotic plaques in apolipoprotein E-null mice. In contrast, recent studies have shown that exogenous PPI injected daily into uremic rats and mice reduces the calcium content in calcified aortas without producing adverse effects on bone. Moreover, TNAP and PHOSPHO1 inhibitors can inhibit vascular calcification. Future studies in HGPS mouse models are thus warranted to investigate whether treatment with PPI in combination with TNAP or PHOSPHO1 inhibitors and FTI and statins is more beneficial than current strategies.

**Acknowledgments:** We thank Simon Bartlett for English editing, María J. Andrés-Manzano for help preparing the figures, and Inés Ortega, Virginia Zorita and the CNIC’s Animal Facility for care of mice.
Funding Sources: Work in the author’s laboratory is supported by grants from the Ministerio de Economía y Competitividad (MINECO) (SAF2010-16044), Instituto de Salud Carlos III (RD06/0014/0021 and RD12/0042/0028) and the Progeria Research Foundation. R.V.-B. holds a Juan de la Cierva postdoctoral contract from MINECO (JCI-2011-09663). CL-O is an Investigator of the Botín Foundation. The Instituto Universitario de Oncología is supported by Obra Social Cajastur and the CNIC by MINECO and Fundación Pro-CNIC.

Conflict of Interest Disclosures: None.

References:


**Figure Legends:**

**Figure 1.** Excessive smooth muscle cell calcification in *Lmna<sup>G609G/+</sup>* mice and VSMCs. 30-32-week-old male *Lmna<sup>G609G/+</sup>* and wild-type mice and derived VSMCs were analyzed. (A)

Representative images (x20) of Alizarin red staining and quantification of calcium deposition
averaged 2-4 aortic cross-sections for each mouse (n=5 mice per genotype). (B, C) qPCR analysis of the osteogenic markers BMP-2 and Runx2 and the calcification inhibitors matrix-Gla protein (MGP) and fetuin A in aorta. Results are means±SEM and are normalized to the level in wild-type mice (n=5 per genotype). (D) Representative images of aortic cross-sections immunostained for Runx2 in wild-type and Lmna<sup>G609G/+</sup> mice. The left panel shows the absence of staining in control experiments with secondary antibody but without anti-Runx2 antibody. (E) Live or lysed VSMCs were maintained in medium containing 1 mM Pi (non-calcifying media) or 2 mM Pi (pro-calcifying media) and calcium deposition was measured and normalized to protein content. The graph on the left shows the results of a representative experiment (means±SEM of six independent wells). The graph on the right shows the inhibition of calcium deposition in pro-calcifying media calculated as the difference between lysed and live cells for each genotype (means±SEM of three independent experiments performed with cells pooled from 10 mice per genotype). **: p<0.01, and #: p<0.0001 versus wild-type.

**Figure 2.** VSMCs expressing progerin exhibit impaired ATP-dependent PPi synthesis and extracellular PPi accumulation. Primary VSMCs were obtained from wild-type and Lmna<sup>G609G/+</sup> mice. (A) Quantification of ePPi accumulated over 2 days in culture. (B) qPCR analysis of ectoenzymes and transporters involved in vascular calcification. (C) Representative immunoblots and quantification of TNAP and eNTPD1 expression after normalization to α-tubulin (a.u., arbitrary units). (D) Alkaline phosphatase activity. Results in A-D are means±SEM of 3 independent experiments. (E) Cells were incubated with 1μM ATP plus 1 μCi/mL [γ<sup>32</sup>P]ATP. At time points indicated in the graphs, inorganic phosphate (Pi), PPi and ATP in the culture medium were separated by thin-layer chromatography. A representative autoradiograph is shown in the
left. The graphs show the quantification of ATP, Pi and PPI. Results are means±SEM of six wells. Similar results were obtained in two additional experiments. *: p<0.05, **: p<0.01 and #: p<0.0001 versus wild-type.

**Figure 3.** VSMCs from progeroid LmnaG609G/+ mice have low ATP levels and mitochondrial dysfunction. Wild-type and LmnaG609G/+ VSMCs were cultured to quantify the level of extracellular ATP (A), intracellular ATP (B), mitochondrial ATP synthesis (C), and the COX/CS activity ratio (D). Results are means±SEM of 12 determinations in two-three independent experiments. #: p<0.0001.

**Figure 4.** Forced progerin expression in VSMCs induces alterations in extracellular PPI metabolism. Primary VSMCs obtained from wild-type mice were infected with retroviral vectors encoding CFP-Lamin A or progerin-CFP. (A) Western blot analysis using anti-GFP antibody. (B) Confocal microscopy to visualize CFP-lamin A and progerin-CFP. (C) qPCR of enzymes and transporters involved in ePPI metabolism. Results are normalized to the mRNA levels in CFP-lamin A controls. (D) Representative immunoblots and quantification of TNAP and eNTPD1 expression after normalization to α-tubulin (a.u., arbitrary units). (E) Determination of extracellular and intracellular ATP, mitochondrial ATP synthesis, COX/CS ratio, and ePPI. Results are means±SEM of three independent experiments. *: p<0.05, **: p<0.01, ***: p<0.001 and #: p<0.0001 versus CFP-Lamin A.

**Figure 5.** PPI homeostasis in mouse plasma and treatment with exogenous PPI. (A) The indicated parameters were analyzed in plasma of 30-32-week-old male wild-type and
These alterations in VSMCs and blood of progeroid \textit{Lmna}^{G609G} mice promote excessive aortic calcification that can be inhibited upon treatment with PPi.
Figure 1

**Wild-type**

Lmna<sup>G609G/+</sup>

**Inhibition of calcium deposition**

(Ca<sup>2+</sup>deposition (P<sub>go</sub>)/P<sub>go</sub> protein)

1 mM 1 mM 2 mM 2 mM

Ca<sup>2+</sup>deposition

Wild-type Lmna<sup>G609G/+</sup>

**Relative mRNA level**

Wild-type Lmna<sup>G609G/+</sup>

BMP-2 Runx2

**Relative mRNA level**

Wild-type Lmna<sup>G609G/+</sup>

MGP Fetuin A

**Inhibition of calcium deposition**

(ΔCa<sup>2+</sup>deposition (µg Ca<sup>2+</sup>/µg of protein))

Wild-type Lmna<sup>G609G/+</sup>

**Runx2**

Wild-type Lmna<sup>G609G/+</sup>

**Control**

Wild-type Lmna<sup>G609G/+</sup>

**Calcium deposition (% total area)**

20 40 60 80

Wild-type Lmna<sup>G609G/+</sup>

**Relative mRNA level**

Wild-type Lmna<sup>G609G/+</sup>

BMP-2 Runx2

**Relative mRNA level**

Wild-type Lmna<sup>G609G/+</sup>

MGP Fetuin A

**Inhibition of calcium deposition**

(ΔCa<sup>2+</sup>deposition (µg Ca<sup>2+</sup>/µg of protein))

Wild-type Lmna<sup>G609G/+</sup>

**Wild-type**

Lmna<sup>G609G/+</sup>

**Control**

Runx2

**Wild-type**

Lmna<sup>G609G/+</sup>

**Runx2**

Wild-type Lmna<sup>G609G/+</sup>

**Calcium deposition (% total area)**

20 40 60 80

Wild-type Lmna<sup>G609G/+</sup>

**Relative mRNA level**

Wild-type Lmna<sup>G609G/+</sup>

BMP-2 Runx2

**Relative mRNA level**

Wild-type Lmna<sup>G609G/+</sup>

MGP Fetuin A

**Inhibition of calcium deposition**

(ΔCa<sup>2+</sup>deposition (µg Ca<sup>2+</sup>/µg of protein))

Wild-type Lmna<sup>G609G/+</sup>

**Wild-type**

Lmna<sup>G609G/+</sup>

**Runx2**

Wild-type Lmna<sup>G609G/+</sup>

**Calcium deposition (% total area)**

20 40 60 80

Wild-type Lmna<sup>G609G/+</sup>

**Relative mRNA level**

Wild-type Lmna<sup>G609G/+</sup>

BMP-2 Runx2

**Relative mRNA level**

Wild-type Lmna<sup>G609G/+</sup>

MGP Fetuin A

**Inhibition of calcium deposition**

(ΔCa<sup>2+</sup>deposition (µg Ca<sup>2+</sup>/µg of protein))

Wild-type Lmna<sup>G609G/+</sup>

**Wild-type**

Lmna<sup>G609G/+</sup>

**Runx2**

Wild-type Lmna<sup>G609G/+</sup>

**Calcium deposition (% total area)**

20 40 60 80

Wild-type Lmna<sup>G609G/+</sup>

**Relative mRNA level**

Wild-type Lmna<sup>G609G/+</sup>

BMP-2 Runx2

**Relative mRNA level**

Wild-type Lmna<sup>G609G/+</sup>

MGP Fetuin A

**Inhibition of calcium deposition**

(ΔCa<sup>2+</sup>deposition (µg Ca<sup>2+</sup>/µg of protein))

Wild-type Lmna<sup>G609G/+</sup>

**Wild-type**

Lmna<sup>G609G/+</sup>

**Runx2**

Wild-type Lmna<sup>G609G/+</sup>

**Calcium deposition (% total area)**

20 40 60 80

Wild-type Lmna<sup>G609G/+</sup>

**Relative mRNA level**

Wild-type Lmna<sup>G609G/+</sup>

BMP-2 Runx2

**Relative mRNA level**

Wild-type Lmna<sup>G609G/+</sup>

MGP Fetuin A

**Inhibition of calcium deposition**

(ΔCa<sup>2+</sup>deposition (µg Ca<sup>2+</sup>/µg of protein))

Wild-type Lmna<sup>G609G/+</sup>

**Wild-type**

Lmna<sup>G609G/+</sup>

**Runx2**

Wild-type Lmna<sup>G609G/+</sup>

**Calcium deposition (% total area)**

20 40 60 80

Wild-type Lmna<sup>G609G/+</sup>

**Relative mRNA level**

Wild-type Lmna<sup>G609G/+</sup>

BMP-2 Runx2

**Relative mRNA level**

Wild-type Lmna<sup>G609G/+</sup>

MGP Fetuin A

**Inhibition of calcium deposition**

(ΔCa<sup>2+</sup>deposition (µg Ca<sup>2+</sup>/µg of protein))

Wild-type Lmna<sup>G609G/+</sup>

**Wild-type**

Lmna<sup>G609G/+</sup>

**Runx2**

Wild-type Lmna<sup>G609G/+</sup>

**Calcium deposition (% total area)**

20 40 60 80

Wild-type Lmna<sup>G609G/+</sup>

**Relative mRNA level**

Wild-type Lmna<sup>G609G/+</sup>

BMP-2 Runx2

**Relative mRNA level**

Wild-type Lmna<sup>G609G/+</sup>

MGP Fetuin A

**Inhibition of calcium deposition**

(ΔCa<sup>2+</sup>deposition (µg Ca<sup>2+</sup>/µg of protein))

Wild-type Lmna<sup>G609G/+</sup>

**Wild-type**

Lmna<sup>G609G/+</sup>

**Runx2**

Wild-type Lmna<sup>G609G/+</sup>

**Calcium deposition (% total area)**

20 40 60 80

Wild-type Lmna<sup>G609G/+</sup>

**Relative mRNA level**

Wild-type Lmna<sup>G609G/+</sup>

BMP-2 Runx2

**Relative mRNA level**

Wild-type Lmna<sup>G609G/+</sup>

MGP Fetuin A

**Inhibition of calcium deposition**

(ΔCa<sup>2+</sup>deposition (µg Ca<sup>2+</sup>/µg of protein))

Wild-type Lmna<sup>G609G/+</sup>

**Wild-type**

Lmna<sup>G609G/+</sup>

**Runx2**

Wild-type Lmna<sup>G609G/+</sup>

**Calcium deposition (% total area)**

20 40 60 80

Wild-type Lmna<sup>G609G/+</sup>

**Relative mRNA level**

Wild-type Lmna<sup>G609G/+</sup>

BMP-2 Runx2

**Relative mRNA level**

Wild-type Lmna<sup>G609G/+</sup>

MGP Fetuin A

**Inhibition of calcium deposition**

(ΔCa<sup>2+</sup>deposition (µg Ca<sup>2+</sup>/µg of protein))

Wild-type Lmna<sup>G609G/+</sup>

**Wild-type**

Lmna<sup>G609G/+</sup>

**Runx2**

Wild-type Lmna<sup>G609G/+</sup>

**Calcium deposition (% total area)**

20 40 60 80

Wild-type Lmna<sup>G609G/+</sup>

**Relative mRNA level**

Wild-type Lmna<sup>G609G/+</sup>

BMP-2 Runx2

**Relative mRNA level**

Wild-type Lmna<sup>G609G/+</sup>

MGP Fetuin A

**Inhibition of calcium deposition**

(ΔCa<sup>2+</sup>deposition (µg Ca<sup>2+</sup>/µg of protein))

Wild-type Lmna<sup>G609G/+</sup>

**Wild-type**

Lmna<sup>G609G/+</sup>

**Runx2**

Wild-type Lmna<sup>G609G/+</sup>

**Calcium deposition (% total area)**

20 40 60 80

Wild-type Lmna<sup>G609G/+</sup>

**Relative mRNA level**

Wild-type Lmna<sup>G609G/+</sup>

BMP-2 Runx2

**Relative mRNA level**

Wild-type Lmna<sup>G609G/+</sup>

MGP Fetuin A

**Inhibition of calcium deposition**

(ΔCa<sup>2+</sup>deposition (µg Ca<sup>2+</sup>/µg of protein))

Wild-type Lmna<sup>G609G/+</sup>
Figure 2

A

B

C

D

E

Phosphatase activity (nmol/min*µg protein)

% total CPM

% total CPM

** Wild-type Lmna<sup>G609G/+</sup>

Relative mRNA levels

TNAP, eNPP1, Pit1, Pit2, eNTPD1, ANK

TNAP/α-tubulin (a.u.)
eNTPD1/α-tubulin (a.u.)

Wild-type Lmna<sup>G609G/+</sup>

Pi

ATP

PPI

Lmna<sup>G609G/+</sup>

20 40 60 80

Time (min)

20 40 60 80

Time (min)
Figure 3

(A) Extracellular ATP (fmol/µg protein) for Wild-type LmnaG609G/+ compared to Intracellular ATP (fmol/µg protein) for Wild-type LmnaG609G/+.

(B) Mitochondrial ATP synthesis (nmol ATP/min/million cell) for Wild-type LmnaG609G/+ compared to COX/CS.

(C) Mitochondrial ATP synthesis (nmol ATP/min/million cell) for Wild-type LmnaG609G/+ compared to COX/CS.

(D) COX/CS for Wild-type LmnaG609G/+ compared to COX/CS.
Figure 4
Figure 6
Defective Extracellular Pyrophosphate Metabolism Promotes Vascular Calcification in a Mouse Model of Hutchinson-Gilford Progeria Syndrome that is Ameliorated upon Pyrophosphate Treatment

Ricardo Villa-Bellosta, José Rivera, Fernando G. Osorio, Rebeca Acín-Pérez, José A. Enríquez, Carlos López-Otín and Vicente Andrés

Circulation. published online May 20, 2013; Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Copyright © 2013 American Heart Association, Inc. All rights reserved. Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/early/2013/05/20/CIRCULATIONAHA.112.000571

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/